GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells
- PMID: 37146586
- DOI: 10.1016/j.stem.2023.04.012
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells
Abstract
Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust chromatin accessibility readout. We applied GTAC to primary acute myeloid leukemia, obtaining high-quality chromatin accessibility profiles and clonal identities for multiple mutations in 88% of cells. We traced chromatin variation throughout clonal evolution, showing the restriction of different clones to distinct differentiation stages. Furthermore, we identified switches in transcription factor motif accessibility associated with a specific combination of driver mutations, which biased transformed progenitors toward a leukemia stem cell-like chromatin state. GTAC is a powerful tool to study clonal heterogeneity across a wide spectrum of pre-malignant and neoplastic conditions.
Keywords: acute myeloid leukemia; cancer evolution; chromatin accessibility; clonal tracking; epigenomics; leukemia stem cells; single-cell ATAC-seq; single-cell technologies; somatic mutation; tumor heterogeneity.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests J.O.J.D. and J.R.H. are co-founders of Nucleome Therapeutics and provide consultancy to the company.
Publication types
MeSH terms
Substances
Grants and funding
- MR/R002258/1/MRC_/Medical Research Council/United Kingdom
- MR/T014067/1/MRC_/Medical Research Council/United Kingdom
- R24 DK106766/DK/NIDDK NIH HHS/United States
- MC_UU_00029/3/MRC_/Medical Research Council/United Kingdom
- MR/L008963/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_00029/8/MRC_/Medical Research Council/United Kingdom
- MR/R008108/1/MRC_/Medical Research Council/United Kingdom
- MR/X001210/1/MRC_/Medical Research Council/United Kingdom
- G1000729/MRC_/Medical Research Council/United Kingdom
- MC_UU_00016/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_00016/11/MRC_/Medical Research Council/United Kingdom
- MC_UU_12009/11/MRC_/Medical Research Council/United Kingdom
- MC_UU_00029/4/MRC_/Medical Research Council/United Kingdom
- MC_U137961146/MRC_/Medical Research Council/United Kingdom
- MC_UU_00016/14/MRC_/Medical Research Council/United Kingdom